Hyperlipoproteinemia type 5

Revision as of 14:43, 16 November 2016 by Shivani Chaparala (talk | contribs)
Jump to navigation Jump to search

WikiDoc Resources for Hyperlipoproteinemia type 5

Articles

Most recent articles on Hyperlipoproteinemia type 5

Most cited articles on Hyperlipoproteinemia type 5

Review articles on Hyperlipoproteinemia type 5

Articles on Hyperlipoproteinemia type 5 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Hyperlipoproteinemia type 5

Images of Hyperlipoproteinemia type 5

Photos of Hyperlipoproteinemia type 5

Podcasts & MP3s on Hyperlipoproteinemia type 5

Videos on Hyperlipoproteinemia type 5

Evidence Based Medicine

Cochrane Collaboration on Hyperlipoproteinemia type 5

Bandolier on Hyperlipoproteinemia type 5

TRIP on Hyperlipoproteinemia type 5

Clinical Trials

Ongoing Trials on Hyperlipoproteinemia type 5 at Clinical Trials.gov

Trial results on Hyperlipoproteinemia type 5

Clinical Trials on Hyperlipoproteinemia type 5 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Hyperlipoproteinemia type 5

NICE Guidance on Hyperlipoproteinemia type 5

NHS PRODIGY Guidance

FDA on Hyperlipoproteinemia type 5

CDC on Hyperlipoproteinemia type 5

Books

Books on Hyperlipoproteinemia type 5

News

Hyperlipoproteinemia type 5 in the news

Be alerted to news on Hyperlipoproteinemia type 5

News trends on Hyperlipoproteinemia type 5

Commentary

Blogs on Hyperlipoproteinemia type 5

Definitions

Definitions of Hyperlipoproteinemia type 5

Patient Resources / Community

Patient resources on Hyperlipoproteinemia type 5

Discussion groups on Hyperlipoproteinemia type 5

Patient Handouts on Hyperlipoproteinemia type 5

Directions to Hospitals Treating Hyperlipoproteinemia type 5

Risk calculators and risk factors for Hyperlipoproteinemia type 5

Healthcare Provider Resources

Symptoms of Hyperlipoproteinemia type 5

Causes & Risk Factors for Hyperlipoproteinemia type 5

Diagnostic studies for Hyperlipoproteinemia type 5

Treatment of Hyperlipoproteinemia type 5

Continuing Medical Education (CME)

CME Programs on Hyperlipoproteinemia type 5

International

Hyperlipoproteinemia type 5 en Espanol

Hyperlipoproteinemia type 5 en Francais

Business

Hyperlipoproteinemia type 5 in the Marketplace

Patents on Hyperlipoproteinemia type 5

Experimental / Informatics

List of terms related to Hyperlipoproteinemia type 5

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Shivani Chaparala M.B.B.S [2]

Synonyms and keywords: : Hyperchylomicronemia,Late-Onset, Hyperchylomicronemia With Hyperprebetalipoproteinemia, Familial, Mixed Hyperlipidemia, Type V Hyperlipemia, Hyperlipidemia Type V, Type 5 Hyperlipoproteinemia, Type 5 Hyperlipemia, Type 5 HPL, Type V HPL, Combined Fat And Carbohydrate Induced Hyperlipidemia, Mixed Hypertriglyceridemia.

Overview

Type 5 Hyperlipoproteinemia (HLP) is a severe type of hyperlipidemia, characterized by an increase in both very-low-density lipoproteins (VLDLs) and chylomicrons in the plasma of fasting subjects on a regular diet. The metabolic defects responsible for type 5 HLP have been a matter of dispute.Although some patients seem to have "primary" type 5 HLP, this phenotype is often associated with secondary factors, eg, diabetes, obesity, alcoholism, nephrotic syndrome, or hypo- thyroidism. Primary type 5 HLP usually appears first in adulthood, a characteristic that distinguishes it from familial deficiency of lipoprotein lipase (type 1 HLP), which is present from birth. Type 5 HLP has been postulated to be the result of a defective clearance of triglycéride (TG)-rich lipoproteins,although lipoprotein lipase is not absent. Another suggested mechanism is of VLDL TG's overproduction.This abnormality could cause an increase in both VLDL and chylomicrons because these two lipoproteins compete with each other for clearance from plasma; in other words, excess production of VLDL alone theoretically could saturate the lipolytic system for plasma TGs and thereby interfere with removal of chylomicrons. It is a more complicated form of type I and more closely related with acquired environmental factors but no association with reduced Lipoprotein lipase or apolipoprotein C-II activity as in type I.

Pathophysiology

The absence of manifestations until middle age, suggest that the cause of type V hyperlipoproteinemia(HLP) is multifactorial including a combination of environmental, hormonal and genetic factors. Patients with type V HLP, the presence of underlying diseases or contributing factors such as Diabetes and alcohol abuse is confirm in 2/3rd of patients and the remaining patients usually show type IV HLP and have hypertriglyceridemia in the family history. VLDL appears to be the most affected lipoproteien fraction in type V and there is 3fold increase in synthesis rate as well as decreased fractional catabolism of VLDL.

Genetics

Precise genetic patterns have not been determined for type V HLP and it has been suggested that type V may be due to number of genetic defects. Among them, the apo E and its isoforms may have an important clinical significance in type V HLP and may affect the catabolism of triglyceride rich lipoproteins. The presence of apo E4 allele may be the genetic factor that predisposes to the development of type V due to delayed lipoprotein clearance.

Associated Conditions

Type V HPL is associated with diabetes mellitus, alcohol abuse, glycogen storage disease type I, Hyperuricemia, Pancreatitis and xanthomatosis.

Causes

Causes of type V hyperlipoproteinemia is more complicated and more closely related to acquired environmental factors. It rarely shows familial occurrence, but its inheritance is variable. Therefore, type V HLP is usually considered to be triggered by acquired environmental factors in individuals with some congenital susceptibility to altered triglyceride metabolism (genetic factors). While the inovolved environmental factors vary, involvement of heavy dirinking, type 2 Diabetes, hormonal therapy and medications are frequently observed.

Causes by Pathophysiology

Congenital (Genetic) Factors Acquired (Environmental) Factors
  • Familial combined hyperlipidemia(FCHL)
  • Monogenic familial hypertriglyceridemia
  • Heterozygous LPL gene abnormality/ Abonormal expression of the LPL gene
  • Other genetic abnormalities
    • Abnormalities of Apo A-V
    • Abnormalities of Apo E

Epidemiology and Demographics

  • Average triglyceride levels in type V hyperlipoproteinemia are lower for women than for men before age 50.
  • In Western population, LPL gene abnormalities were observed in 10% of patients with type V HLP.

Risk Factors

Natural History, Complications and Prognosis

Complications

Diagnosis

Diagnostic Criteria

Definitely diagnosed if both I and II are fulfilled.

Symptoms

Laboratory Findings

Treatment

Pharmacotherapy

NOTE:Caution against possible exacerbation of glucose tolerance is necessary in the treatment of Diabetic patients with Nicotinic acid.

Secondary Prevention

  • Strict restriction of fat intake
  • Elimination of acquired environmental factors
  • Weight reduction

References